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Background: The ‘predictD algorithm’ provides an estimate of the level and profile of risk of the onset of major
depression in primary care attendees. This gives us the opportunity to develop interventions to prevent depression in a
personalized way. We aim to evaluate the effectiveness, cost-effectiveness and cost-utility of a new intervention,
personalized and implemented by family physicians (FPs), to prevent the onset of episodes of major depression.
Methods/Design: This is a multicenter randomized controlled trial (RCT), with cluster assignment by health center and
two parallel arms. Two interventions will be applied by FPs, usual care versus the new intervention predictD-CCRT.
The latter has four components: a training workshop for FPs; communicating the level and profile of risk of depression;
building up a tailored bio-psycho-family-social intervention by FPs to prevent depression; offering a booklet to prevent
depression; and activating and empowering patients. We will recruit a systematic random sample of 3286 non-depressed
adult patients (1643 in each trial arm), nested in 140 FPs and 70 health centers from 7 Spanish cities. All patients will be
evaluated at baseline, 6, 12 and 18 months. The level and profile of risk of depression will be communicated to patients
by the FPs in the intervention practices at baseline, 6 and 12 months. Our primary outcome will be the cumulative
incidence of major depression (measured by CIDI each 6 months) over 18 months of follow-up. Secondary outcomes will
be health-related quality of life (SF-12 and EuroQol), and measurements of cost-effectiveness and cost-utility. The
inferences will be made at patient level. We shall undertake an intention-to-treat effectiveness analysis and will handle
missing data using multiple imputations. We will perform multi-level logistic regressions and will adjust for the probability
of the onset of major depression at 12 months measured at baseline as well as for unbalanced variables if appropriate.
The economic evaluation will be approached from two perspectives, societal and health system.
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Discussion: To our knowledge, this will be the first RCT of universal primary prevention for depression in adults and the
first to test a personalized intervention implemented by FPs. We discuss possible biases as well as other limitations.
Trial registration: ClinicalTrials.gov identifier: NCT01151982
Keywords: Depression, Primary prevention, Primary health care, Randomized controlled trialBackground
Depression as a public health problem
In the European community, major depression is the most
common single mental disorder, with a 12 month preva-
lence of 4% [1], reaching 7% in USA [2]; and in European
primary care attendees increasing to 13.9% in woman and
8.5% in men [3], or 14% in Spain [4]. A systematic review
of 24 cost-of-illness studies of depression has reported
that depression has substantial economic consequences
for society [5]. For example, in 2004 the total annual cost
of depression in Europe was estimated to be €118 billion,
or €253 per inhabitant [6]. Major depression is projected
to rank as the greatest contributor to illness burden by
2030 in high-income countries [7] due to its high preva-
lence, high impact on functioning, and early age of onset
[8]. Most suicides are committed by people with depression
[9], and the mortality rate of depressed patients exceeds
1.65 times that of the general population [10]. Despite
effective treatments for depression, curative interventions
can only reduce the disease burden of depression by 20%,
because not all cases are recognized as such, and when
recognized not all will receive appropriate treatment or
adhere to the given treatment [11]. From a public health
point of view, besides improving the whole process of
depression care [12], we need comprehensive approaches
to depression prevention [13].
Risk strategies and primary prevention of depression
Primary prevention aims to reduce the incidence of
new episodes of depression. When preventive measures
are applied to the general population, regardless of
their risk factors, primary prevention is called “univer-
sal prevention”. All randomized controlled trials (RCT)
of universal prevention of depression have been
conducted in children and/or adolescentes [14,15]. If
primary prevention strategies are applied to people who
have risk factors for depression, then it is called “selective
prevention”. Here RCT have been undertaken in children
and adolescents [16,17], elderly people [18,19], and in
adults with specific risks for depression: stroke [20], post-
partum [21-23], cancer [24], diabetes [25], macular degen-
eration [26], patients with complex medically illnesses
[27], caregivers of relatives with dementia [28], or social
risk patients [29], among others. A particular group of
people at risk of depression are those with depressive
symptoms, which do not meet DSM-IV diagnostic criteriafor major depression. Primary prevention in this group of
105 people who are "subclinically depressed" is referred to
“indicated prevention” [30-32].
The ‘predictD’ algorithm
In recent years, our research group has developed and
validated a risk algorithm (“the predictD algorithm”) to
predict the onset of episodes of major depression in primary
care attendees, in Europe [33] and Spain [34]. The Spanish
algorithm obtained good calibration and discriminative
validation [C-index = 0.82 (0.79-0.84)]. From 39 known
risk factors of depression, 12 were included in the Spanish
prediction model: six were patient characteristics or past
events (sex, age, sex*age interaction, education, child-
hood physical abuse, and lifetime depression) and six were
current status (SF-12 physical score, SF-12 mental score,
dissatisfaction with unpaid work, number of serious prob-
lems in very close persons, dissatisfaction with living to-
gether at home, and taking medication for stress, anxiety
or depression). The calculator of the likelihood of becoming
depressed at 12 months is accessible at http://www.rediapp.
org/predict.php. The "predictD algorithm" provides, in
addition to the quantification of the overall risk of de-
pression, knowledge of those risk factors influencing a
given patient and that could guide a possible preventive
intervention. This could allow us, as in cardiovascular
disease, to develop interventions tailored in both inten-
sity (level of risk) and specificity (profile of risk). This
type of primary prevention might be called “personal-
ized prevention” [35,36].
Effectiveness of primary prevention in depression
There are at least 5 systematic reviews or meta-analyses
[37-41] of effectiveness of primary prevention in depres-
sion in children and/or adolescents. A systematic review
on Australian school-based prevention for anxiety and
depression [37] included 24 RCT of 9 intervention pro-
grams (Friends, moodGYM, Aussie Optimism, etc.). Six
were universal interventions, two indicated programs and
one was a treatment program. Most were associated with
short-term improvements or symptom reduction at follow-
up. A meta-analysis (13–4 RCT) [38] of school-based
cognitive-behavior interventions to prevent depression
(all interventions were delivered at the group level) found
that they were effective for reducing depressive symptoms
at 1 and 3 months (with statistical significance), but at 6
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meta-regression of other meta-analyses [39] (47 RCT
and 32 prevention programs) found larger effects for
programs targeting high-risk individuals, samples with
more females, samples with older adolescents, programs
with a shorter duration and with homework assignments,
and programs delivered by mental health professional
interventionists versus teachers. Another systematic re-
view [40] (42 RCT, relating to 28 individual school-based
programs) also found that indicated programs were
most effective, and teacher program leaders less effective.
The most recent Cochrane meta-analysis [41] (15–10
RCT) concluded that the risk of having a depressive dis-
order post-intervention was reduced at 3, 9 and
12 months; although there was significant heterogeneity.
The persistence of the findings suggests that this is real
and not a placebo effect.
A recent meta-analysis (20 RCT) [42] focusing on pre-
vention of postpartum depression, reported a Relative Risk
of 0.68 (95% CI: 0.66-0.93). Promising interventions in-
cluded the provision of intensive, professionally-based
postpartum home visits, telephone-based peer support,
and interpersonal psychotherapy. A meta-analysis [43]
of psychosocial preventive interventions to reduce depres-
sive symptoms in low socio-economic-status women (14
RCT) found an overall effect size of 0.31(95% CI:0.17-0.45).
A meta-analysis (4 RCT) [20] identified a significant effect
(Odds Ratio:0.64; 95% CI:0.42-0.98) of psychotherapy for
preventing depression after stroke, but there is no evi-
dence of efficacy of antidepressants in preventing depres-
sion (10 pharmaceuticals RCT) [20].
On the other hand, there are 4 meta-analyses [44-47]
that mixed different types of populations. The first [44]
evaluated 7 RCT of psychological treatments for patients
with subthreshold depression. The relative risk of develop-
ing a major depressive disorder in subjects who received
the intervention was 0.70 (95% CI: 0.47-1.03). The second
[45], combining 6 RCT that used cognitive-behavioral train-
ing called “coping with depression” to prevent depression,
found an Incidence Rate Ratio (IRR) of 0.62 (95% CI: 0.43-
0.91). The third [46] (19 RCTand 21 comparisons) included
different types of prevention (universal:2, selective:11 and
indicated:8), age (adolescents: 9 and adults:12), interven-
tions (cognitive-behavioral:15, interpersonal:3 and others:3),
format (groups:18 and individual:3), target group (postpar-
tum:7, school:6 and other:8), and type of prevention (uni-
versal:2, selective:11 and indicated:8). The combined IRR
was 0.78 (95% CI: 0.65-0.93). A fourth meta-analysis [47]
adding 11 further RCT to the previous meta-analysis [46]
reported an IRR of 0.74 (95% CI: 0.65-0.85).
Justification
Data suggest that interventions to prevent depression
are effective, although this effect seems small or moderateand there are a number of limitations: 1) a lack of evi-
dence on longer term follow-up; 2) many RCT had sam-
ples of insufficient size to find significant differences for
the incidence of new depression cases; 3) data suggest
that universal prevention has a lower effect than selective
and indicated prevention, although this affirmation is only
applicable for school-based interventions, since no RCT
has applied universal prevention in adults; and 4) there
are no conclusive data on the superiority of any one inter-
vention. On the other hand, cost-effectiveness studies on
prevention of depression are scarce [48-50], so further
investigations are needed to decide on the general imple-
mentation of primary prevention programs for depres-
sion [51,52].
Most primary prevention of cardiovascular diseases is
performed in primary care and the community, while
specialists (cardiologists, endocrinologists, nutritionists, etc.)
play a role more focused on complicated and serious cases.
This is also the case in depression. The target for primary
prevention of depression is the healthy person and thus it
is reasonable that primary prevention of depression is car-
ried out in primary care and the community. However, few
RCT of primary prevention of depression are conducted in
primary care [28,29,32], and all the interventions were
implemented by specialists in mental health (therapists,
psychologists, psychiatric nurses, etc.).
We aim to conduct a cluster randomized trial in pri-
mary care with a new intervention to prevent the onset
of major depression, based on the level and profile of
risk of depression (personalized prevention), involving
adult patients at low, moderate and high risk as mea-
sured by a risk algorithm (universal prevention) and
implemented by family physicians (FPs). We will recruit
a sample of non- depressed primary care patients that is
large enough to detect a significant reduction in the in-
cidence of new episodes of depression over 18 months.
Our main outcome will be the effectiveness of this new
intervention, but we will also assess its cost-
effectiveness and cost-utility.
Objectives
The main objective is to measure the effectiveness of a
new intervention for primary prevention of major depres-
sion based on the level and profile of risk of primary care
attendees. Among the secondary objectives are to evaluate
the cost-effectiveness and cost-utility of the intervention
versus usual care.
Methods/design
Design
A multicenter randomized controlled trial, with cluster
assignment by health center and two parallel arms. Two
interventions will be applied: usual care in the control
group and a new intervention for primary prevention of
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patients. These interventions will be applied by the FPs.
The main outcome is the cumulative incidence of major
depression during the follow-up, with evaluations at base-
line, 6, 12 and 18 months. Inferences will be made at the
patient level.
The predictD-CCRT study is in compliance with the
Helsinki Declaration. The predictD-CCRT study has been
approved by the relevant ethics committees in each par-
ticipating Spanish city: Ethics Committee on Human
Research of the University of Granada, Ethics and Research
Committee of Primary Health District of Malaga, Ethics
Committee for Clinical Research of Sant Joan de Deu
Foundation (Barcelona) (PIC CEIC-62-09), Ethics Com-
mittee for Clinical Research of Aragon (CEICA) (CP06/
05/2009), Ethics Committee for Health Research of the
Jaen Hospital, Ethics Committee for Clinical Research
of Euskadi (CEIC-E) (03/2009), Ethics Committee for
Clinical Research of the Rio Hortega Hospital of Valladolid
(04/2009).
Setting
Health Centers in seven Spanish cities will participate:
Malaga, Jaen and Granada in southern Spain; Valladolid
in western Spain; Saragossa and Bilbao in northern Spain;
and Barcelona in eastern Spain. Each health center covers
a population of 15,000 to 30,000 inhabitants from a geo-
graphically defined area. The FPs in each health center
work as a group, with extensive primary care teams. The
Spanish National Health Service provides free medical
cover to over 95% of the population. Patients can visit
their doctors as often as they want without having to pay
for it, even when they do so for preventive reasons. Each
patient is assigned to only one FP, who has gatekeeper
functions.
Sample selection of participants and exclusion criteria
Health centers
From a possible total of 220 health centers in the 7 par-
ticipating cities, those that do not have electronic clinical
charts or have had them for less than 2 years or plan to
change them in the next 18 months will be excluded. All
others will be invited to participate. From those centers
that agree to participate, a random sample of 10 health
centers per city, 70 health centers in total, will be selected.
These will then be randomized by an independent person
from the research group at the coordinating center of the
study (Malaga), using closed and opaque envelopes.
Family physicians
In each participating health center we will exclude those
FPs who are unfamiliar with using the clinical chart or
are planning to change their place of work in the next
18 months. We shall then invite all remaining FPs toparticipate and from those who agree, randomly select
two per center (before randomization of centers) using
closed and opaque envelopes selected by an independent
person from the research group. This will mean 140 FPs
will participate in the trial.
Patients
Patients belonging to the 140 FPs will be selected using
a systematic random sampling, each 4–6 patients, from
the FPs’ appointment lists at random starting points for
each day. This will be done by an assistant researcher
for each health center. The list of selected patients will
be given every day to the family physician (FP) before
starting to see patients. FPs will check the selected patients
to see if they meet any of the following exclusion criteria:
age under 18 or over 75 years; inability to understand or
speak Spanish; severe mental disorder (psychosis, bipolar,
personality disorder,…); cognitive impairment; terminal ill-
ness; the patient is scheduled to be out of the city more
than four months during the 18 months of the follow-up;
and persons (representatives) who attend the surgery on
behalf of the person who has the appointment. The FPs will
introduce the study to the selected not excluded patients
and will request permission before contacting the assistant
researcher. Patients who refuse to participate will not
be replaced, prolonging the days of recruitment to achieve
26–27 patients for each FP. Those who give informed con-
sent will undertake a research interview within two weeks
with the Composite International Diagnostic Interview
(CIDI) in order to detect the presence of major depres-
sion. Patients with a diagnosis of current major depression
will also be excluded from the trial. The exclusion criteria
for health centers, FPs and patients are shown in Table 1.
Randomized allocation
The randomization and allocation to the arms will be
carried out according to the health center; that is, all FPs
and patients from one health center will be included in
the same arm. If the same health center has FPs in both
the control and the intervention groups, the likelihood
of the FPs in the control group becoming contaminated
by the intervention group is high, since Spanish health
centers generally work as a team. We aim to evaluate a
new intervention for primary prevention of major depres-
sion, which in principle will be delivered at patient level
by the FP; however, due to the nature of the intervention
some components could be delivered at community level,
so the contamination between patients in the control and
intervention groups in the same health center is likely.
Therefore we have decided on cluster randomization to
avoid this possibility in patients and FPs.
The randomization of the 70 health centers to allocate
them to the control or intervention groups will be done
stratifying by city. Thus, we will have 35 health centers
Table 1 Exclusion criteria of the predictD-CCRT study
Health centers
• Do not have electronic clinical charts or have had them for less than
2 years
• Plan to change their electronic clinical charts in the next 18 months
• No consent to participate in the study
Family Physicians
• Unfamiliar with using the clinical chart
• Planning to change their place of work in the next 18 months
• No consent to participate in the study
Patients
• Age under 18 or over 75 years
• Inability to understand or speak Spanish
• Severe mental disorder (psychosis, bipolar, personality disorder…)
• Cognitive impairment
• Terminal illness
• The patient is scheduled to be out of the city more than four months
during the 18 months of follow-up
• Persons (representatives) who attend the surgery on behalf of the
person who has the appointment
• Diagnosed with major depression by the CIDI*
• No consent to participate in the study
* Composite International Diagnostic Interview.
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group, 5 and 5 respectively for each one of the seven cities
participating in our study. The randomization will be
undertaken centrally, from the coordinating center in
Malaga, by an independent person outside the research
group using closed and opaque envelopes.
Masking
In trials that evaluate psychosocial interventions it is not
possible for professionals who provide the new interven-
tion or for patients who receive it to be blind to it [53].
However, in our trial those who assess outcomes (inter-
viewers) will be different and independent from those
who provide the intervention (FPs). Moreover, the inter-
viewers will be not informed of the patient’s status in the
control or intervention group. Those who perform stat-
istical analyses will also be blind to the intervention and
control codes.
Sample size
The sample size was calculated assuming that the cumula-
tive incidence of depression in the control group will be
12% [34] while the incidence in the intervention group
will be 5 points below that 12%. The Type I error of the
chosen contrast was 5% and the power 80%. The sample
size obtained assuming a simple random sample would be
430 people in each group. As we will undertake a cluster
randomization (by health center), and decided to have 35
health centers in the control group and 35 in theintervention group (48 patients in each health center),
we obtained an effect design of 3.82, with the assump-
tion that the intraclass correlation coefficient of the
health center is 0.06 [34]. Thus we need a sample size of
1643 patients in each trial arm, making a global sample
of 3286 patients, 140 family doctors and 70 health cen-
ters. These calculations assume that the distribution
of 2 FPs per health center and 24 patients per FP will
be very homogeneous (coefficients of variation of
cluster sizes <0.15). We also expect to increase the
sample of patients recruited by FPs from 24 to 26–
27, since about 10% of potential patients will have a
diagnosis of major depression on CIDI at baseline
and will need to be excluded.
Follow-up
All patients enrolled in the trial will be evaluated at base-
line, 6, 12 and 18 months. Interviewers trained and inde-
pendent from the FPs providing usual care or the new
intervention will administer the CIDI and the other ques-
tionnaires. FPs participating in the trial will complete a
self-administered questionnaire at baseline.
Variables
Main outcome
Our primary outcome will be the cumulative incidence
of major depression during 18 months of follow-up. We
will use the section of depression of the CIDI [54,55],
developed and validated by the WHO [56]. The CIDI is
a fully structured diagnostic interview that provides current
diagnoses according to DSM-IV categories. We will use
it to estimate the onset of major depression in each
prior 6-month period (0–6, 6–12, and 12–18 months).
Interviewing in this way, at baseline, 6, 12 and 18 months,
we will obtain the most accurate picture of the cumulative
incidence of major depression.
Secondary outcomes
As secondary outcomes we will use measurements of
health-related quality of life using the 12-item Short Form
(SF-12) [57,58] and the EuroQol [59-61] with evaluations
at baseline, 6, 12 and 18 months. Furthermore, we will
make estimates of cost-effectiveness and cost-utility (see
Economic evaluation below).
Independent variables
Patient variables
 Socio-demographic characteristics: province, sex,
age, marital status (married/living with partner,
separated, widowed, divorced or single),
employment status (employed, unemployed/looking
for a job, retired, unable to work, looking after
family or home, in full-time education, and other),
educational level (beyond secondary education,
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incomplete primary education/illiterate),
owner-occupier of an accommodation (owner,
mortgage, rented, and other), living alone or with
others [62].
 Anxiety disorders using the anxiety section of the
Primary Care Evaluation of Mental Disorders
(PRIME-MD) [63]. The Spanish version of the
PRIME-MD can classify patients who test positive
for panic attack, generalized anxiety disorder and
other anxiety disorders [64]. We will use a
dichotomous anxiety variable to indicate when any
of the three diagnoses of anxiety are present in a
given patient.
 Controls, demands and rewards for unpaid work,
using an adapted 7 item version of the job content
instrument [65]. From the sum of the seven items,
the variable is categorized in 3 (satisfied, dissatisfied
and very dissatisfied).This questionnaire has
previously shown good validity and reliability in
Spain [62].
 Satisfied with living together at home (5-Likert
response options).
 A lifetime screen for depression based on the first
two questions of the CIDI [66].
 Childhood experiences of physical abuse (5-Likert
response options) [67].
 Presence of serious physical, psychological or
substance misuse problems, or any serious disability,
in persons who are close friends or relations of
participants. These questions can be used as 4
different items (yes/no) or as an ordinal variable
(summation of the 4 questions).
 Whether the participant’s mother committed suicide
(yes/no) [68].
 Perception of safety inside and outside the home
using a question from the Health Surveys for
England with 5-Likert response options [69].
 Experiences of discrimination on the grounds of
sex, age, ethnicity, appearance, disability, sexual
orientation, and others using 7 questions (yes/no)
from a European study [70]. The answers to these
seven items can also be joined in an ordinal
variable.
 Taking medication for anxiety, depression or stress
in the previous 6 months (yes/no).
 Probability of the onset of major depression at
12 months, obtained from the equation “predictD-
Spain”, which has been previously validated [34]
and is derived from a combination of some of the
above variables.
We will assess all these variables and questionnaires at
baseline, 6, 12 and 18 months. The test–retest reliabilityof questions used in the predictD studies has been
reported previously [62,71].
Family physician variables The FP variables will be
collected through a self-administered questionnaire at
baseline:
 Age and gender.
 Job characteristics: urban or rural clinic, type of
contract (fixed or temporary/substitute), months
working at the current Health Center, list size and
mean time per visit.
 Training: year medical degree, time working as FP
(in months), postgraduate training (3 or 4 years) in
family medicine (yes/no), accreditation as a FP tutor
(yes/no), experience in training FPs [resident 1st year
assigned (yes/no), and/or resident 3rd or 4th year
assigned (yes/no)], and membership of Spanish
Health & Communication group (yes/no).
 Satisfaction with management of patients with
mental health disorders in primary care: degree of
comfort in the use of antidepressants (5-Likert
response options), satisfaction with communication
and care shared with the mental health team
(secondary care) (5-Likert response options),
satisfaction with the role of primary care nurse in
mental health disorders (5-Likert response options)
and satisfaction with the role of primary care social
worker in mental health disorders (5-Likert
response options or “I do not have social worker in
my health center”).
 Profile of professional practice: A three-dimensional
questionnaire about professional satisfaction (4 items),
workload perception (4 items), and biomedical vs.
psychosocial orientation (4 items) validated in
Spain [72].
 Personality according to the Spanish version of the
Eysenck Personality Questionnaire-Revised (EPQR-A)
[73-75], which explores three dimensions:
extraversion, neuroticism, and psychoticism.
Health center variables From administrative records
we will collect at baseline the following variables: inhabi-
tants of the health center area (Basic Zone Area), size of
the population where the health center is located, num-
ber of professionals (also by type of professionals) in the
health center, population/professional ratios, and time of
functioning as health center.
Statistical analysis
In line with recommendations by Groenwold [76], we
will perform effectiveness analyses in the following ways:
analysis with covariate adjustment and 2) intention-to-
treat analysis by multiple imputations with covariate
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release 12.1 [77].
Multiple imputations
We will use multiple imputations by chained equations
[78] by means of the ‘ICE’ program [79]. We will choose
a number of imputations to limit the loss in power (no
more than 1%) for testing the association of interest [80].
We will undertake a sensitivity analysis to check the
changes in the estimates and variances with progressive
increases in the number of imputations [78]. We will ex-
plore the plausibility of the missing at random assumption
and will include in the imputation models any covariate of
interest that is predictive of missingness [81]. When we
have to impute a covariate, we will also include the outcome
variable in the imputation model. Standard errors will be
calculated using Rubin’s rules [82] which take account of
the variability in results between the imputed datasets,
reflecting the uncertainty associated with the missing values.
Regression models
We will perform multi-level logistic regressions with the
cumulative incidence of depression at 18 months as the
dependent variable. To test the hierarchical data structure
we will use the likelihood-ratio test of the null model with
health center as a random factor versus usual logistic re-
gression. Then we will check the likelihood-ratio test of
the null model with health center and FP as random fac-
tors versus the null model with only health center. We will
also calculate the intraclass correlation coefficients for
health center and FP.
We will include in the models the group variable (con-
trol and intervention) and will adjust for the probability of
the onset of major depression at 12 months measured at
baseline [34]. Where appropriate we will adjust for unbal-
anced variables at baseline not included in the equation to
predict the onset of major depression [34]. We also will
retain in the model the variable city because of an a priori
assumption of clustering effect within city, although it has
few categories (n = 7) that could be considered as random
factors [83]. From the final model we will obtain the
adjusted odds ratio (OR) of the group variable and the
adjusted number needed to treat, NNT ¼ 1lo 1−ORð Þ [Io =
cumulative incidence in control group], to prevent a
case of major depression.
Inverse probability weighting
For each patient the probability of remaining in the
follow-up at 18 months will be obtained through a logis-
tic regression model (multilevel if appropriate) with the
variable ‘remaining in the follow-up’ (yes/no) as dependent
variable and a set of predictor variables measured at base-
line. For the effectiveness analyses with complete cases wewill apply the inverse probability weighting to the final
model to adjust for a possible attrition bias due to partici-
pants lost during the follow-up [84,85], implemented
through the ‘GLLAMM’ program [86].
Economic evaluation
The Economic Evaluation will be presented from two per-
spectives: 1) a Societal Perspective, including the costs of
all types of health services (direct costs) and the costs
that stem from production losses (indirect costs); and 2)
Health System (including only direct costs). Although
NICE [87] recommends just performing economic evalua-
tions from the Health System perspective, we will present
both due to the major impact that depression has on
productivity [6,88,89]. The time frame of this study will
be 18 months. Therefore, we will discount both costs
and effects at 3.5% following NICE recommendations
[87]. All costs will be expressed in euros (€) for the
reference year 2012.
Cost
We will use a modified version of the Client Service Re-
ceipt Inventory (CSRI) [90] to collect information about
use of health care resources, use of psychotropic drugs
(antidepressants, anxiolytics and hypnotic-sedatives) and
lost productivity.
Unit costs
Direct health costs will be calculated by multiplying the
number of health service units (consultations, hospital
days, etc.) by their standard cost price. This unit cost will
be retrieved from ‘Oblikue dataset’ (http://www.oblikue.
com/). Cost of medication will be calculated by multiply-
ing cost price per daily dose, multiplied by the number
of prescription days recommended, as recalled by the
patient. Information about medication costs will be obtained
from the Spanish Pharmaceutical Vademecum (http://www.
vademecum.es/). Indirect costs consist of the costs of absen-
teeism from paid work. Costs of work loss will be calculated
by multiplying the days on sick leave by the minimum daily
wage in Spain according to the human capital approach.
Intervention costs will include only the printed leaflet.
However, we will also identify primary care visits related
directly to the predictD-CCRT intervention.
Health effects
The difference in the cumulative incidence of depression
at 18 months will be measured as stated in the paragraph
described above (‘main outcome’). Quality Adjusted Life
Years. (QALYs) will be measured using the EuroQol-5D.
Spanish tariffs will be used to estimate the utility of health
states described by the patients [91,92]. QALYs will be
calculated by multiplying the utility by the amount of
time a patient spent in a particular health state. Linear
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states. QALYs will be assessed at baseline, 6, 12 and
18 months.
Cost effectiveness and cost-utility analysis
As in the effectiveness analyses, we will take two ap-
proaches to the cost-effectiveness and cost-utility analyses:
1) a complete case analysis with covariate adjustment and
2) an analysis after multiple imputations with covariate
adjustment. For the first strategy we will apply the inverse
probability weighting to the final model. We will calculate
incremental cost-effectiveness ratios (ICER), which are
calculated as incremental cost (mean cost for intervention
group minus mean cost for control group) divided by in-
cremental effectiveness (mean effect for intervention
group minus mean effect for control group) [93]. Incre-
mental cost-utility ratios (ICUR) will be calculated in the
same way. The only difference is that the effect will be the
difference in QALYs. The incremental costs and incremental
health effects will be modeled by generalized linear models
(GLM). The modified Parks test will be used in order to se-
lect the appropriate family. In order to identify the correct
link function we will compare model performance of all per-
mutations of candidate link and variance function using dif-
ferent diagnostic tests such as the Pregibon Link test, the
Hosmer-Lemoshow test and the Copas test [93]. We will
check the intraclass correlation coefficients and the
likelihood-ratio tests with health center, FP and both as we
said before. If the clustering effect is relevant, we will use
robust standard errors for the cluster indicated.
Quantification of uncertainty
To estimate the uncertainty around the ICER and ICUR,
we will calculate 95% confidence intervals around the
mean cost differences using the non-parametric confi-
dence interval. Bootstrapping with 5000 replications will
be performed on each imputed dataset [93,94].
Generation of cost-effectiveness planes and cost-
effectiveness acceptability curves
Bootstrapped cost effect pairs will then be plotted on cost
effectiveness planes and used to estimate cost effectiveness
acceptability curves (CEACs). In the cost-effectiveness
planes the ‘x’ axis represents the difference in effects and
the ‘y’ axis the difference in costs. CEACs show the prob-
ability that a treatment is cost effective at a specific ceiling
ratio, which is the amount of money society is willing to
pay to gain one extra unit of effect. Willingness to pay
values will range from 0€ to 100,000€ [95].
Sensitivity analyses
A number of sensitivity analyses will be conducted in order
to assess the robustness of the results. Among others, these
analyses will include: modification of the unit cost ofdifferent values such as primary care physician visits or
nurse practitioner; modification of discount rates (from 0%
to 6% as NICE recommends); modification of the cost for
absenteeism (using the mean salary instead of the mini-
mum); and modification of the cost including loss of prod-
uctivity by presenteeism.
Intervention
The new intervention will be applied at patient level by
the FPs in the intervention group. This intervention will
be tailored to each patient based on his/her risk profile
of depression (risk factors present) and his/her risk level
(likelihood of becoming depressed at 12 months), and it
will be built up from a total of 5 components, which
may act both independently and interdependently [96]:
1) Training workshop for family physicians in the
intervention group
A qualitative research study conducted prior to this
RCT [97] found that FPs were resistant to informing
their patients about their risk of depression, and also
raised doubts about the validity of the predictD risk
algorithm. FPs said they had little training on
prevention of depression, and expressed uncertainties
about what they should advise their patients. They
were also fearful about the possible distress that could
result in patients being informed of their risk for
depression and commented on the lack of time for
these preventive activities. Accordingly, the FPs will
receive a 10–15 hour training workshop during
working hours in the new intervention. This will
enable them: 1) to interpret and make a specific and
global evaluation of the risk for depression for each
patient; 2) to transmit this information to the patient
in an understandable and comprehensible way,
without causing alarm; 3) to undertake active listening
to patients about their beliefs, expectations and
impact on information transmitted; 4) to provide
tailored advice for each patient depending on his/her
set of modifiable risk factors for depression; 5) to be
able to integrate and personalize advice to give each
patient based on his/her health history, previous
doctor-patient relationship and bio-psycho-family-
social circumstances; 6) to support those patients
excessively worried by the information given. In the
workshop we will use role-playing and video
comments in groups in order to discuss and practice
with FPs how to deal with different situations. The
educational units, that we will use, are shown in
Additional file 1: Annex 1. Previously, we will
“train the trainers” to ensure that the training of the
FPs will be performed to a minimum standard of
quality and in standardized manner in each of the
cities participating in the study.
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depression
How patients are informed about their risk of
becoming ill (cardiovascular events, hip fractures…)
determines the outcome of prevention efforts
[98,99]. In the same qualitative study as mentioned
above, we found that primary care patients are
pleased to be informed of their risk for depression
[97]. Communicating with patients about their level
and risk profile for depression is very new as until
now there have been no validated risk algorithms to
predict its onset [33,34]. This is also “the starting
component”, which will activate the other
components of the intervention. Each FP will receive
(at baseline, 6 and 12 months) a report with the
information on risk from each of 24 patients not
depressed at baseline (belonging to their usual
patient list) who will be randomly selected and will
provide informed consent to participate in the study.
This report will include the likelihood of becoming
depressed at 12 months and the patients’ responsesFigure 1 Example of the mechanisms to reduce the likelihood of becoming
depression by the family physician.to each of the risk factors included in the predictD-
Spain equation [34]. An example of a report of a
patient who has 24.4% of becoming depressed at
12 months is shown in Figure 1.
If a patient has a moderate or high risk level
(2nd or 3rd tertile), the FP will arrange an
appointment with the patient aiming to communicate
his/her risk of depression. If a patient has a low risk
(1st tertile), the FP will have the option to report by
telephone or face to face depending on the patient’s
preferences. If a visit is scheduled, this will last
approximately 10 minutes. This process of
transmitting risk information will be held at baseline,
6 and 12 months. Reports will not include
information about major depression diagnosis by CIDI
at 6 and 12 months; although we will recommend
that FPs screen for depression if the risk of depression
was moderate or high at 6 and 12 months. FPs will
write down on the problem list (clinical chart) the
label “predictD” in order to remind them on opening
their clinical charts that patients are included in thedepressed after the intervention to prevent the onset of
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help to ensure that when patients see their FPs,
regardless of the reason for the consultation,
doctors will take into account the information on
their risk of depression if applicable.
3) Building up a tailored bio-psycho-family-social
intervention to prevent depression by family physicians
Unlike psychosocial interventions developed to date to
prevent depression, our intervention will be provided
by FPs. With this approach we intend to draw on and
integrate those usual components of primary care that
could converge in the prevention of depression:
1. Previous knowledge and doctor-patient
relationship: Family physician’s commitment to
the patient has no defined end point. This
continuity of the relationship and attention over
time helps FPs to acquire a comprehensive
understanding of the health problems, illness
behavior, coping style, cultural background, and
family and social context of their patients.
Moreover, most patients will develop trusting
relationship with their FPs. Patients will feel free to
expose personal aspects of their lives in order to
receive help, and FPs will need less time to know
and understand particular aspects of any situation.
2. Establishment of a basic psychotherapeutic
relationship: Many patients already consider FPs
to be their primary source of mental care [100],
although many FPs are not aware of this. Patients
expressed this idea when asked about who would
be the most appropriate person to communicate
their risk of depression [97]. An interview in
which a FP tries to communicate adequately to
the patient his/her level and risk profile of
depression will encourage the patient to express
his/her concerns about the circumstances and
problems that, in his/her opinion, could
precipitate depression. FPs will then actively
listen and offer an emphatic response, gathering
additional and relevant information where needed
and giving any advice if appropriate. The patient
and the FP could agree to schedule a new visit to
continue talking about preventing depression, but
the only mandatory visits that FPs will arrange
are those to report the risk of depression at
baseline, 6 and 12 months. These are not
psychiatric interviews or formal
psychotherapeutic interventions, but may give the
opportunity for the patient to feel heard and
understood from a cognitive and emotional
standpoint [101]. It is also intended to help the
patient to be activated and empowered.3. Family-oriented practice: FPs often bring a family
orientation to bear in their clinical practice [102].
It has been reported that there are up to 5 levels
of family-centered medical care in primary care
[103]. We believe that the FP in our study are at
the third level: FPs take an active interest in the
feelings and concerns of the family in an
empathic way. Family-oriented practice should be
understood from the system theory, so that a
change in any element of the family system
could prevent depression in the patient. For
example, a FP could help to improve the quality
of life of a person who has the responsibility of
caring for a relative with Alzheimer’s Disease and
this may prevent depression [28]. This is feasible
because in Spain members of the same family
usually share the same FP. Primary care patients
think it is useful to involve the family and
consider the family resources and the possibility
of involving other family members in coping with
the risk of depression [97].
4. Social prescribing and community referral by FPs:
Many social and personal problems cannot be
dealt with effectively by the FP and require
community resources [104]. The social dimension
of the practice of primary care is the least
accepted by FPs [105] and little is known about
the effect on health of social prescribing and
community referral by the FP. However, we will
encourage FPs in the intervention group to
become familiar with the community resources in
their area. We will advise them on using centers.
Moreover, we will advise them on using social
prescribing in patients deemed appropriate with
the aim of preventing depression. Primary care
patients suggested participation in informal support
groups to help them restructure their lives [97].
5. Management of physical problems: some physical
problems are considered risk factors for
depression, such as serious diseases (cancer, heart
attack, stroke, …) [20,24], disabling illness
(blindness, deafness, arthritis, …) [26] and/or
chronic health problems (diabetes, chronic pain, …)
[25]. Moreover, in our predictD studies [33,34]
poor physical quality of life was an important
predictor of depression, and FPs will receive this
information in the patient’s reports. Therefore,
appropriate management of physical problems
could also help prevent depression.4) Offering a booklet to prevent depression
At the first intervention visit, at baseline, FPs will
give patients a brief booklet (a diptych) with advice
for preventing depression (Additional file 1: Annex 2).
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health promotion and preventive activities of the "
Spanish Family and Community Medicine Society",
in its section on mental health (PAPPS) [106]. At the
end of this booklet reference is made to three websites
with information for patients and relatives about
depression, anxiety and insomnia [107].5) Activating and empowering patients
People have favorable attitudes and beliefs about
prevention of depression that do not conflict with
evidence-based programs [100,108]. Activating and
empowering patients to act on this knowledge might
lead to an increased perception of self-efficacy,
which is the gateway to changing attitudes and
behavior to prevent depression. Primary care
patients are in favor of receiving information about
their risk for depression from their FP but seeking
solutions themselves, with or without the help of the
FP [97]. We will encourage FPs to invite patients to
make suggestions during the interview on strategies,
attitudes and behaviors they are already using to
prevent depression. FPs will then positively reinforce
those that in their opinion are the most appropriate to
prevent depression for each patient.Explanatory model for the prevention of depression in
primary care
Figure 2 shows the theoretical model that integrates the
five components of the intervention to prevent depres-
sion from primary care: There are patient’s internal risk
factors (sex, age, gene, personality, etc.) and external fac-
tors (threatening events) that can trigger an episode of
major depression, depending on internal (coping style)
and external (family and social support) resources that
might be activated. Firstly, we introduce in the system
“the training workshop” for FPs (component 1) to im-
prove their knowledge, attitudes and skills to prevent de-
pression with the new intervention. The FP usually has
previous knowledge and a doctor-patient relationship
(component 3.1) that generally predisposes toward a bet-
ter intervention to prevent depression by both doctor
and patient. We will give FPs risk information from pa-
tients, which they will use to communicate their level
and profile of risk of depression (component 2). This is
the “starting component” that will activate the rest of
the components, creating a new doctor-patient inter-
action, whose essential element is the establishment of a
basic psychotherapeutic relationship (component 3.2). The
family-oriented practice (component 3.3), social prescribing
and community referral (component 3.4), and manage-
ment of physical problems (component 3.5) might be acti-
vated or not depending on the risk factors of depression
involved in each patient, the FP’s skills, and the patient’spreferences. In all cases, FPs should provide the booklet to
prevent depression (component 4), although the patient
may or may not decide to use it. Finally, the FPs, taking
into account the above components, will encourage
their patients to speak about those strategies, attitudes
and behavior they are already doing to prevent depres-
sion, in order to achieve their activation and empower-
ment (component 5). Thus, the patients can improve their
perception of self-efficacy, which in turn promotes
changes in attitudes and behaviors to prevent depression.
There are also internal (sex, personality, psychosocial and
preventive orientation, etc.) and external (work stress,
team support, etc.) factors in the doctors that may influ-
ence their ability to conduct a successful intervention. The
differences between interventions to prevent depression
conducted so far in adults and the new intervention that
we propose in primary care are summarized in Table 2. An
example of how the intervention can lead to a reduced risk
for depression is shown in Figure 1, and another example
on the doctor-patient interview to prevent depression can
be seen in a video (Additional file 1: Annex 3).
Quality control of the intervention
In order to control the satisfaction and adherence to the
intervention we will undertake two quality controls. The
first one will be from a subjective focus. After each inter-
view to inform patients about their risk of depression,
the FPs will have to answer four questions: Have I writ-
ten the label “predictD” in the clinical chart? (yes/no);
what is my level of satisfaction with this interview to re-
port the risk of depression? (5-Likert response options);
would I change anything in this interview? (open an-
swer); and observations (open answer). All patients will
be asked about their overall satisfaction with their doctor
(5-Likert response options); and only patients receiving
the intervention will respond to the question “What is
your level of satisfaction with the last interview in which
your doctor informed you about your risk of depression?”
(5-Likert-5 response options or “I was not informed”).
The second is from an objective focus: we will review the
clinical charts to confirm that FPs have included the label
“predictD” on the problem list and we will also collect the
number and content of visits related to the intervention.
Side effects of the intervention
It is possible that some patients will react with fear or
worry when receiving information about their level and
risk profile of depression, especially apprehensive patients
or those that already have a high level of anxiety. If a pa-
tient does not want to receive this information he/she will
not sign the consent and therefore will be excluded from
the study. This will be valid for each evaluation point. As
stated in component 5 of the intervention, we will train
FPs to support those patients excessively worried by the
Explanatory model for the prevention of 
the onset of depression in primary care
Preventing 
major 
depression 
Patient
Internal Factors
- Age-sex
- Gene factors
- Education level
- Personality
- Coping style
- Quality of life 
(physical &mental) 
External 
Factors
- Social support
- Stressful events
Perception of 
self-efficacy
Activation
Empowerment
(5)
Attitudinal 
and 
behavioral
change
Prior interaction
Family Physician
Internal Factors
- Age-sex
- Personality
- Job satisfaction
- Psychosocial orientation
- Preventive orientation
External Factors
-Work stress
-Time per patient
- Health Centre Team 
support
Information on 
patient’s level & risk 
profile (2)
New interaction (3)
Training (1)
Booklet (4)
Figure 2 Explanatory model for the prevention of the onset of depression by family physicians. Component 1 (training of family physician)
prepares the family physicians for the intervention and component 2 (communicating the level and risk profile of depression to the patient) initiates it.
This leads to a new doctor-patient interaction, which triggers component 3 (building up a tailored bio-psycho-family-social intervention to prevent
depression by family physicians) that activates and empowers the patient (component 5), and which increases the patient’s perception of self-efficacy.
This can also be achieved by component 4 (offering the patient the booklet) at the first doctor-patient interview.
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that occurs during the intervention. We will also evaluate
the impact of the predictD-CCRT intervention on anxiety
symptoms through measurements of the PRIME-MD
[63,64] at each evaluation point of the follow-up.The intervention for the control group
Patients in the control group will receive “usual care”; that
is, the kind of care that FPs usually provide when they are
unaware of the risk profile for depression in the patients.Table 2 Differences between interventions to prevent the ons
intervention in primary care
Characteristics Other interventions
Type of prevention Selective or indicated1
Orientation Psychosocial (cognitive-behavioral, inte
or psychoeducational
Type of intervention Formal (fixed rules)
Same number of sessions for all patie
Same components for all patients
Who implements the intervention? Therapists or specialists in mental hea
(psychologist, psychiatric nurse…)
Sample size Small
1 Patients with a specific risk of depression, high risk or subclinically depressed.
2 Patients with a low, moderate or high risk of depression. To date universal interve
and adolescents.This means explicitly that the patients and FPs in the con-
trol groups will not be informed about the risk profile at
any point. FPs in the control group will not receive the
training workshop.Discussion
Ethical considerations
FPs who do not meet exclusion criteria will be asked to
sign an informed consent form before health centers are
allocated to the control or intervention group. Once theet of depression evaluated so far in adults and the new
New intervention
Universal2
rpersonal…) Biopsychosocial (primary care orientation) and based on
level and risk profile of becoming depressed (personalized)
Not formal (tailored rules)
nts Minimum of three interviews but no maximum
Number of components involved tailored
lth Family physicians
Large
ntions have been evaluated to prevent depression but only in children
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intervention groups, selected patients who do not meet
exclusion criteria in the health centers of the control
group will be asked for consent to follow-up and in the
intervention group to receive the intervention and to
follow-up. In each health center a research assistant will
ask participants to sign informed consent forms. In brief,
participants in the intervention group will be informed
about the purpose of the trial, the expected duration of
their participation, trial procedures, foreseeable risks or
inconveniences, expected benefits, whom to contact for
further information, their rights as participants, and that
their participation is voluntary and that they may refuse
to participate or withdraw from the trial at any time,
without penalty or loss of benefits. Since the identity of
patients will not be known at the time when randomization
of health centers is to be carried out, it will not be possible
to seek their consent in advance of randomization. Neverthe-
less, FPs will provide consent to participate in the trial; more-
over, none of them will be involved as a researcher in this
study, so there should not in theory be a conflict of interest.
In view of the fact that so far there is no evidence that the
new intervention being evaluated in this study is effective,
and given that it is generally the responsibility of FPs to put
the medical interests of their patients above all other consid-
erations, this may be an appropriate choice [109].
Strengths and limitations
To our knowledge, this is the first RCT of universal pri-
mary prevention for depression in adults and the first to
test a personalized intervention implemented by FPs. We
will recruit a large sample of patients and will continue the
follow-up for 18 months. We will use a structured inter-
view (CIDI) to exclude patients with major depression at
baseline and to assess the cumulative incidence of major
depression during follow-up. However, our study also has
several limitations.
The cluster randomization by health center will
minimize possible contamination bias. However, some
degree of contamination could happen, since health centers
of both control and intervention arms are located in the
same city. This bias will be against the hypothesis of the
study. The cluster randomization might produce a good
balance between groups (health center); however, this
does not guarantee a good balance at other levels [109]
(FPs and patients). We will check at baseline the imbal-
ance at the three levels and will adjust for it when ap-
propriate. This and the adjustment at baseline for the
likelihood of becoming depressed at 12 months will re-
duce our confounding bias.
As mentioned before, because we evaluate a psycho-
social intervention, it is not possible for the FPs who
provide it and patients that receive it to be blind [53], so
FPs and patients can change their behavior because theyfeel observed and included in the intervention group
(Hawthorne bias). FPs of the control group could also
change their behavior, but it is less likely in patients
from this group because they will only give their in-
formed consent for the follow-up.
If many health centers and FPs refuse to participate,
we could encounter a selection bias as the FPs who choose
to participate may have a different profile (psychosocial
orientation, different training and work satisfaction, etc.)
to those who do not. This could limit external validity
[110] and, from a pragmatic standpoint, the new inter-
vention would be less effective when applied as a general
program. Similar biases could occur if a large proportion
of patients refuse to participate. It is not easy to obtain in-
formation from those physicians and patients who refuse
to participate, so it will be difficult to ascertain the direc-
tion of this possible selection bias. As stated above, for the
analyses with complete cases we will use the inverse prob-
ability weighting [84,85] to adjust for a possible attrition
bias due to participants lost during the follow-up. We will
use multiple imputations to minimize attrition bias and
maintain statistical power [78,111].
The results obtained will be applicable to primary care
attendees and cannot necessarily be generalized to other
settings such as the general population. Nevertheless,
primary care is an ideal setting for prevention and at-
tendees are generally (because of health and social prob-
lems) at greater risk of depression than the general
population.
If the predictD-CCRT intervention proves effective, it
will be difficult to determine which of the 5 components
are active or expendable, and how each interacts with the
others. We will conduct a number of secondary analyses
that could provide clues to the most relevant component,
but more studies (quantitative and qualitative) specifically
directed toward that goal will be needed.Additional file
Additional file 1: Annex 1. Training workshop in the predictd-CCRT
intervention: educational units. Annex 2. Primary prevention of major
depression based on the level and risk profile of primary care attendees.
Annex 3. A video example of the predictD-CCRT intervention.Abbreviations
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